Non-Sponsored Content
Acalabrutinib FDA approved for treatment of adult patients with pre-treated mantle cell lymphoma
By: News Feed | Last updated: 31st October 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
acalabrutinib, Acerta Pharma, AstraZeneca, AZ, Calquence, FDA, lymphoma, MCL
On 31 October 2017, the FDA granted accelerated approval to acalabrutinib (Calquence®, AstraZeneca under license of Acerta Pharma BV) for treatment of adult patients with mantle cell lymphoma (MCL) and pre-treated with one or more prior therapy.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!